ONCODES.PREC.MED. EO-34 Market Cap ($5.08 Million)
Market Cap & Net Worth: ONCODES.PREC.MED. EO-34 (ZR8)
ONCODES.PREC.MED. EO-34 market cap. ONCODES.PREC.MED. EO-34 (F:ZR8) has a market capitalization of $5.08 Million (€4.35 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #28500 globally and #2452 in its home market, demonstrating a -25.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONCODES.PREC.MED. EO-34's stock price €0.23 by its total outstanding shares 19067385 (19.07 Million).
ONCODES.PREC.MED. EO-34 Market Cap History (2022–2026)
ONCODES.PREC.MED. EO-34 market cap history from 2022 to 2026. Data shows change from $40.01 Million to $5.08 Million (-40.42% CAGR). Check ONCODES.PREC.MED. EO-34 (ZR8) share price today for real-time trading data and today's change.
ONCODES.PREC.MED. EO-34 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONCODES.PREC.MED. EO-34's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ZR8 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
77.74x
ONCODES.PREC.MED. EO-34's market cap is 77.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $40.01 Million | $7.98 Million | -$231.18K | 5.01x | N/A |
| 2023 | $38.45 Million | $1.07 Million | -$8.09 Million | 35.86x | N/A |
| 2024 | $16.09 Million | $207.04K | -$7.21 Million | 77.74x | N/A |
Competitor Companies of ZR8 by Market Capitalization
Companies near ONCODES.PREC.MED. EO-34 in the global market cap rankings as of November 3, 2026. Also see ONCODES.PREC.MED. EO-34 (ZR8) total assets for a full breakdown of the balance sheet.
Key companies related to ONCODES.PREC.MED. EO-34 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of ONCODES.PREC.MED. EO-34 (2022–2026)
Market capitalization of ONCODES.PREC.MED. EO-34 from 2022 to today. Between 2022 and today, ONCODES.PREC.MED. EO-34's market cap moved from $40.01 Million to $ 5.08 Million, with a yearly change of -40.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.08 Million | -36.84% |
| 2025 | €8.05 Million | -50.00% |
| 2024 | €16.09 Million | -58.14% |
| 2023 | €38.45 Million | -3.90% |
| 2022 | €40.01 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of ONCODES.PREC.MED. EO-34 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.08 Million USD |
| MoneyControl | $5.08 Million USD |
| MarketWatch | $5.08 Million USD |
| marketcap.company | $5.08 Million USD |
| Reuters | $5.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more